Urinary thromboxane and risk of cardiovascular events: role of aspirin-Reference-Cited by-同舟云学术

Urinary thromboxane and risk of cardiovascular events: role of aspirin

Published:2024-03-06 Issue:15 Volume:45 Page:1368-1370
ISSN:0195-668X
Container-title:European Heart Journal
language:en
Short-container-title:

Author:

Eikelboom John W¹^ORCID,Kruger Paul C²^ORCID

Affiliation:

1. Population Health Research Institute, Thrombosis and Atherosclerosis Research Institute, Hamilton Health Sciences Corporation and McMaster University , Hamilton, L8L 2X2 Ontario , Canada

2. Department of Haematology, Fiona Stanley Hospital , Perth , Australia

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/eurheartj/article-pdf/45/15/1368/57230508/ehae003.pdf

Reference14 articles.

1. Aspirin;Awtry;Circulation,2000

2. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism;Egan;Circulation,2005

3. Metabolism of thomboxane B2 in man. Identification of twenty urinary metabolites;Roberts;J Biol Chem,1981

4. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events;Eikelboom;Circulation,2002

5. Urinary 11-dehydro-thromboxane B2 and mortality in patients with stable coronary artery disease;McCullough;Am J Cardiol,2017

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The importance of prevention in high-risk patients: peripheral artery disease, renal failure, and diabetes;European Heart Journal;2024-04-14